恩替卡韦在慢性乙型肝炎治疗中的应用效果分析

Effect Analysis of Entecavir in the Treatment of Chronic Hepatitis B

目的探究在慢性乙型肝炎治疗中恩替卡韦的应用效果。方法本次研究共计随机抽选100例慢性乙型肝炎患者为对象,入院时间均在2019年1月至2020年1月,以数字标注法为基准将其分成2个小组,常规组和试验组各50例,治疗中分别使用拉米夫定和恩替卡韦,比较2个小组用药疗效、不良反应以及肝功能、生化指标变化。结果治疗12个月后的天门冬氨酸氨基转移酶(AST)、谷丙转氨酶(ALT)、乙肝病毒基因(HBV-DNA)、乙肝e抗原(HBeAg)水平试验组更低,与常规组差异显著(P<0.05)。治疗总有效率试验组(96.00%)患者比常规组(82.00%)更高,差异显著(P<0.05)。用药不良反应率试验组(18.00%)患者比常规组(36.00%)更低,差异显著(P<0.05)。结论慢性乙型肝炎患者在临床治疗中恩替卡韦的抗病毒效果显著,对病情转归有着良好作用,而且用药安全性高,患者能有很好的耐受性,适合长期服用,值得深入推广应用。

Objective To investigate the effect of entecavir in the treatment of chronic hepatitis b.Methods This study randomly selected 100 patients with chronic hepatitis b,hospital time in January 2019 to January 2020,based on digital annotation method who will be divided into two groups,50 cases of normal group and experimental group,lamivudine and entecavir were used respectively,and the study compared the drug curative effect,adverse reaction and the change of liver function and biochemical indexes of the two groups.Results After 12 months of treatment,the levels of aspartate aminotransferase (AST),alanine aminotransferase (ALT),hepatitis B virus gene (HBV-DNA) and hepatitis B E antigen (HBeAg) in experimental group were significantly lower than those in conventional group (P<0.05).The total effective rate of experimental group (96.00%) was higher than that of conventional group (82.00%),and the difference was significant (P<0.05).The rate of ADR in experimental group (18.00%) was lower than that in conventional group (36.00%),and the difference was significant (P<0.05).Conclusion Entecavir has significant antiviral effect in the clinical treatment of patients with chronic hepatitis b,and has a good effect on the prognosis of the disease.Moreover,the drug safety is high,and patients can have a good tolerance.Therefore,it is suitable for long-term use and worthy of further promotion and application.